Abstract
Gestrinone has been shown to reduce uterine volume and stop bleeding in women with uterine leiomyomata. In the present study, we demonstrated a reduction in the volume of uterine myomas and in the uterine artery blood perfusion over a 6-month period of gestrinone administration in premenopausal women.
MeSH terms
-
Adult
-
Estrogen Antagonists / therapeutic use*
-
Female
-
Gestrinone / therapeutic use*
-
Humans
-
Leiomyomatosis / blood supply*
-
Leiomyomatosis / diagnostic imaging
-
Leiomyomatosis / drug therapy*
-
Premenopause
-
Regional Blood Flow / drug effects
-
Time Factors
-
Treatment Outcome
-
Ultrasonography
-
Uterine Neoplasms / blood supply*
-
Uterine Neoplasms / diagnostic imaging
-
Uterine Neoplasms / drug therapy*
Substances
-
Estrogen Antagonists
-
Gestrinone